Xenetic Biosciences (XBIO) Other Operating Expenses (2011 - 2020)
Xenetic Biosciences' (XBIO) quarterly Other Operating Expenses came in at $9.2 million in Q3 2020, up 43.22% YoY from $6.5 million in Q4 2019, and up 43.22% on a QoQ basis from $6.5 million in Q3 2019.
Xenetic Biosciences (XBIO) Other Operating Expenses (2011 - 2020) Analysis & Trends
Xenetic Biosciences (XBIO) has 6 years of Other Operating Expenses data on file, last reported at $9.2 million in Q3 2020.
- Quarterly Other Operating Expenses rose 43.22% year-over-year to $9.2 million in Q3 2020, while the trailing twelve-month figure through Jun 2021 was $9.2 million (up 43.22% YoY) and the FY2020 annual result came in at $9.2 million, up 181.51% from the prior year.
- Other Operating Expenses climbed to $9.2 million in Q3 2020, from $6.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $9.2 million in Q3 2020 to a low of $6.5 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 9.24 Mn |
| Sep 30, 2019 | 6.45 Mn |
| Mar 31, 2014 | -1.07 Mn |
| Nov 30, 2013 | 78,936.00 |
| May 31, 2013 | 39,814.00 |
| Feb 28, 2013 | 14,315.00 |
| Nov 30, 2012 | 44,246.00 |
| May 31, 2012 | 72,056.00 |
| Feb 29, 2012 | 62,034.00 |
| Nov 30, 2011 | 28,566.00 |